A detailed history of Eaton Vance Management transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, Eaton Vance Management holds 70,682 shares of IONS stock, worth $2.83 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
70,682
Previous 69,598 1.56%
Holding current value
$2.83 Million
Previous $2.58 Million 21.39%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

BUY
$36.54 - $48.66 $39,609 - $52,747
1,084 Added 1.56%
70,682 $3.13 Million
Q2 2022

Aug 15, 2022

BUY
$31.71 - $43.0 $413,276 - $560,419
13,033 Added 23.04%
69,598 $2.58 Million
Q1 2022

May 16, 2022

BUY
$29.88 - $37.04 $862,725 - $1.07 Million
28,873 Added 104.26%
56,565 $2.1 Million
Q4 2021

Feb 14, 2022

BUY
$25.61 - $35.1 $20,948 - $28,711
818 Added 3.04%
27,692 $803,000
Q3 2021

Nov 15, 2021

SELL
$33.54 - $40.55 $6,708 - $8,109
-200 Reduced 0.74%
26,874 $885,000
Q2 2021

Aug 16, 2021

BUY
$34.54 - $47.25 $20,862 - $28,539
604 Added 2.28%
27,074 $1.08 Million
Q4 2020

Feb 12, 2021

BUY
$45.3 - $60.27 $24,779 - $32,967
547 Added 2.11%
26,470 $1.5 Million
Q3 2020

Nov 13, 2020

BUY
$47.45 - $62.95 $139,455 - $185,010
2,939 Added 12.79%
25,923 $1.23 Million
Q2 2020

Aug 13, 2020

BUY
$46.85 - $61.05 $155,776 - $202,991
3,325 Added 16.91%
22,984 $1.36 Million
Q1 2020

May 14, 2020

BUY
$41.6 - $63.4 $124 - $190
3 Added 0.02%
19,659 $929,000
Q4 2019

Feb 11, 2020

BUY
$53.85 - $65.27 $161 - $195
3 Added 0.02%
19,656 $1.19 Million
Q2 2019

Aug 16, 2019

BUY
$62.09 - $86.14 $723,534 - $1 Million
11,653 Added 145.66%
19,653 $1.26 Million
Q1 2018

May 07, 2018

BUY
$44.08 - $55.05 $352,640 - $440,400
8,000 New
8,000 $353,000

Others Institutions Holding IONS

About IONIS PHARMACEUTICALS INC


  • Ticker IONS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,940,992
  • Market Cap $5.69B
  • Description
  • Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...
More about IONS
Track This Portfolio

Track Eaton Vance Management Portfolio

Follow Eaton Vance Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eaton Vance Management, based on Form 13F filings with the SEC.

News

Stay updated on Eaton Vance Management with notifications on news.